Targeting device therapy: genomics of sudden death.
Targeting device therapy: genomics of sudden death.
复制标题
靶向装置治疗：猝死的基因组学。
DOI：
10.1016/j.hfc.2009.08.005
复制
发表时间：
2010
影响因子：
3.4
通讯作者：
London,Barry
中科院分区：
文献类型：
--
作者：
Frangiskakis,JMichael;London,Barry
Sudden cardiac death (SCD), which is usually defined as death from cardiac causes within an hour of symptom onset, affects more than 3 million people annually worldwide. 1 In the United States, estimates of annual sudden deaths range from 200,000 to 450,000, but are typically cited as accounting for 300,000 annually. 2 With an estimated population of 300 million people in the United States, approximately 1/1,000 will die suddenly each year.Clinical factors used to predict sudden death include a prior history of aborted sudden death, left ventricular dysfunction, and the diagnosis of inherited syndromes associated with arrhythmias such as hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, and Brugada syndrome. 3, 4 Diagnostic studies such as programmed electrical stimulation and T-wave alternans have proved disappointing, and the majority of SCD occurs in people without overt risk factors. 5 Pharmacological therapy, with the exception of β-adrenergic blockade, does not prevent SCD. 6 Implantable cardioverter defibrillators (ICDs) are effective therapy for those at risk for SCD, but their use is associated with complications during implantation, device and lead failure, inappropriate shocks, limitations to quality of life, and cost. 7 In addition, when used as primary prevention for SCD in cardiomyopathy, as many as 10 ICDs must be placed to prevent one sudden death.
